Science & Technology: The Evolution of Oncologic Drug Development

| 01 January 2009

Despite a doubling in the number of candidates in the cancer drug pipeline from 1990 through 2006, the overall US approval rate for cancer drugs remains low (8%).1

 

© 2022 Regulatory Affairs Professionals Society.

Discover more of what matters to you

No taxonomy